# A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors

Source: https://onco.cc/trials/nct04440735/  
OnCo record `nct04440735` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Atezolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Kahr Medical, active and no longer recruiting.

## Summary

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04440735 by Kahr Medical, with 125 participants planned, started 2020-10-07 and due to reach its primary completion in 2025-09. Interventions recorded: DSP107, Atezolizumab. Conditions listed: Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04440735
- Phase: 1/2
- Setting: A First-in-Human, Two-Part, Open-Label, Phase I/II Study of DSP107 in Subjects with Advanced Solid Tumors Including a Dose-escalation Safety Study (part 1) and Preliminary Efficacy Assessment of DSP107 As Monotherapy and in Combination with Atezolizumab (part 2)
- Sponsor: Kahr Medical
- Enrolled: 125

## Sources

- ClinicalTrials.gov NCT04440735: https://clinicaltrials.gov/study/NCT04440735

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct04440735.json